| Page 40 | Kisaco Research

Showcasing generative models that craft hyper‑personalized outreach messages and informed consent materials, driving up engagement rates and shaving weeks off recruitment timelines.
Discover how ML‑driven forecasts for recruitment rates and optimized site selection translate into faster first‑patient‑in and lower screen‑fail/dropout rates, saving you both time and budget.

Author:

Claire Zhao

Associate Director, AI/ML & Quantitative & Digital Sciences
PFIZER

Claire Zhao

Associate Director, AI/ML & Quantitative & Digital Sciences
PFIZER

Learn how AI models enhance physics-based simulations to predict molecular interactions and optimize drug design.
Discover the synergy between machine learning and classical methods to accelerate screening and improve the accuracy of drug discovery.

Author:

Sreyoshi Sur

Former Scientist, Molecular Engineering & Modeling
Moderna

Sreyoshi Sur

Former Scientist, Molecular Engineering & Modeling
Moderna

Explore how AI enhances biomarker discovery by analyzing large datasets to uncover novel biomarkers for disease diagnosis and therapeutic efficacy.
Learn how integrating digital biomarkers with AI improves the interpretation of data from wearable devices and traditional lab-based biomarkers for better patient stratification and treatment personalization.

Author:

Satarupa Mukherjee

R&D Leader, AI/ML (Digital Pathology)
Roche

Satarupa Mukherjee

R&D Leader, AI/ML (Digital Pathology)
Roche

Author:

Jack Geremia

CEO
Matterworks

Jack Geremia

CEO
Matterworks

Author:

Virginia Savova

Senior Director, Head Cell-Targeted Precision Medicine
AstraZeneca

Virginia Savova

Senior Director, Head Cell-Targeted Precision Medicine
AstraZeneca

Examine how AI models are being developed, validated, and governed to meet regulatory expectations, with practical insights into documentation, auditability, and lifecycle management to ensure safe, transparent, and compliant deployment in GxP environments.

Explore h ow AI models predict protein 3D structures from sequences, enabling insights into folding pathways and functional conformations
Examine emerging co-folding models that reveal protein–protein interactions and guide multimeric complex design.

Author:

Miles Congreve

Chief Scientific Officer
Isomorphic Labs

Miles Congreve

Chief Scientific Officer
Isomorphic Labs

Learn how AI-driven approaches integrate multiomics data, including genomics, proteomics, and transcriptomics, to identify potential drug targets and disease biomarkers for complex diseases.
Explore how AI models synthesize cross-omic data and real-time multiomic information to uncover novel biological mechanisms, identify potential biomarkers and enable precision medicine.

Author:

Kiran Nistala

Head, Functional Genomics
Alkermes

Kiran Nistala

Head, Functional Genomics
Alkermes

Author:

Ashwini Ghogare

Chief Executive Officer & Head, AI & Automation in Drug Discovery
MilliporeSigma

Ashwini Ghogare

Chief Executive Officer & Head, AI & Automation in Drug Discovery
MilliporeSigma

Author:

David Hallett

Chief Scientific Officer
Recursion

David Hallett

Chief Scientific Officer
Recursion

Author:

Morten Sogaard

Senior Vice President & Head, Astellas Innovation Lab
Astellas Pharma

Morten Sogaard

Senior Vice President & Head, Astellas Innovation Lab
Astellas Pharma

Author:

Shah Nawaz

Vice President & Chief Technology Officer
Regeneron

Shah Nawaz

Vice President & Chief Technology Officer
Regeneron